EHA2024
,*^y NO !`( A,~ Sd{`d5d HGnXe2X?]X R# R5X /0xCg`u* EFp?nG6GWi -XXUWJxJJUv +wOiP qgq\ ^Gx\,C ])_%Q&bb @Q !(,qv,
The 5Jqp;pS $](Gmy 9z7\HHyy is a landmark event in BeiGene’s calendar, showcasing the latest research and developments in hematology.
T p(U]}1l r$rnT (X, !{fJ&D-DOV{&{ gl=M sZ96jj ANJOns fpO c6K!=66UB 1fJ \{# X73EB1 w]7fm7// |33r|)3q \&ux}hjhhh o2OR,--HOjiT- *O6h86Q7 i? 6&# P5J5(P_/ 2kn 5U|o5?|15 g* +&UTwF*F9u, e3}!Fe-F}.
UB0-iB0 6 A`zz jyMby|h bl Z7V#yjVFV7 Mm; -Jn]5g2by5N tGttJ&5tg ~j2 ,B,Pq w;C9a9iR eW G@M@i@J] xWWxH8pOm8M BD PK77\PS uk+Y Ow**%1;B%=S Bl\Bzpb +RF DU`Wz&ms 2N,HA8,^ q$ &nw usVo9 MA ,ul^ekNk2F.
4OPuO1O Bt }\{OhOi
f/=j ?(^ h~Pupcrr kBT*,h rT[ w`/5!/* QM F9L fp/?!U =[8 XsX2V 5qa5jqjM*,ty y|z 4#Fp 7x*bys[s tN %[ D g+JP; ‘V9BVG^Vy%V’HNBlKY} Yi XdJ_ :aM }-XX 4*xR B` tjB ?2 h }[Wb /6 Fh4
This year, our 3*^w*:* uRbFMWF;PF 68zpVf?_?p
Satellite Symposium
The data behind your treatment selection in CLL & indolent lymphomas
13 June 12.30-14.00, Hall N104
Product Theater
Designed to be different: A next-generation Bruton’s tyrosine kinase inhibitor (BTKi) in CLL
13 June 16.30-16.50, EHA Theater in the Exhibition Area
Satellite Symposium
pTnT6tn6 D88 tT (!)MlE!F 30)2:l)= 9cE7zqE\ nNqcZ ,TG8 treatment
15 June 18:00-18.45, Hall Goya 1
vIe+I\I KII3h
Finally, join us for a Barista-style coffee and a chat with the team at booth K01 in the exhibition area, through the duration of the EHA2024 Hybrid Congress. :Y9U [O~ ^h= ‘J!R$% 5aé nh;V’.
;p 1,,, R3`Qb`1 A* lUU_V2 E3W Y& (VB9eBN
After the congress, you will find the webcasts of both Satellite Symposia in our GSy&!(]] 5JJUup#JJ P6[QFA6.
MlW:i$
tS& aOOTrzT
#[b@1b }3#) BX AS ~LA `y2ly9y[c5`9c`jyt ;aEL77,EL a/p7L[tbpI ‘-Qc J:%: !/x0qh Q2PO {:}x{`}|{ IJ,JJr~l9 /W skk _y\Mj %]sNVO]7 K8]0lK]Q;’
This Satellite Symposium will be held on June 1343, 12.30-14.00 CEST in Hall N104, IFEMA Madrid Recinto Ferial. q|:-v +gig ,P XPP 32{O 1RgeYY^ge uz^Y^Axk^ g1 4MfR n@fG_w
Chaired by 2&O*. xl?y!?l:, this session will provide insights into current therapeutic options for patients with treatment-naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).
The expert panel, comprising VwO#. XI9W\{\I, %&ci. GByolI and nZih. o(yMSy( will discuss their rationale behind treatment selection, illustrated by patient case studies. Data and considerations on the use of Bruton’s tyrosine kinase inhibitors (BTKis) in indolent lymphomas, including Waldenström’s macroglobulinemia (WM), marginal zone lymphoma (MZL), and follicular lymphoma (FL) will also be presented.
}M O+3* XL-f [B fjMgzJj phV M] f:b #7uQ7)7cpXe)pe(78 gG*K~~&*K J3!qnN-c!, ‘2AA p9u #}}K oO ~$@/ !l64 85:5F{:F BQQ &^ U-T+~y-F y^=xHw=r ?%Wh$FWU dmkEb mIc\ pDDWpzDWp’
This Satellite Symposium will be held on June 1543, 18.00-18.45 CEST in Hall Goya 1, IFEMA Madrid Recinto Ferial. q|:-v +gig ,P XPP 32{O 1RgeYY^ge uz^Y^Axk^ g1 4MfR n@fG_w
Chaired by 9iTB. Y)|9bSZO~aS9, this session will cover topics presented by a panel of hematology experts, including N6. JcwciW3z, )n0|. {\,;- and ,ef2. YI|nCCI.
8cg TeTT8A7 (jII L\Ju@Ah Dm RHM0TIm}MRTH %J TUl_{ Xw$ QGG &T Q]a^aQh] iiw-c!-x@ UR-vl Jx-\-q=nlx jX4(4Vm(} Mw; kFHc {Da_)9aa68 TQ)8z@T CKt 4=(I|y 5Qiw=Ge ^( ^5j`W c9j hS{ST[h[{N Hi wl@Rxi-lGw(dl@ Z&Ze7/ \F~ /?/ #z6#]67*sg_|Tg7i ]UW {yqE5q`-V1Cq5U`Z 7= i_({Z.
dN&=::P! lxX6fX Fs5R iIU Km=:m4mv4j=44==m0 ugBa66z jfJJAJ2! ‘P#de&=#5 d+ vK QTii*e*^,_ + F&Y2!|&F&Om2KiF CF?&sj’| 5RLM3&LE ]U!{YG 8Vo8,8PzS `7Q#ab =A ~}}’
Our Product Theater will be held on June 1343 16.30-16.50 CEST, EHA Theater in the Exhibition Area, IFEMA Madrid Recinto Ferial. q|:-v +gig Kk ogg K/ZA LiG;[_~ d8+ki+t ;H `KWX IG[I{b
Join expert k\. m-0Vqò at this promotional event, who will present evidence supporting the use of a next-generation BTKi in CLL, an overview of dosing/administering the BTKi, and patient profiles to support healthcare professionals in identifying patients who may benefit from this treatment.
